The reported in vivo and in vitro results of assessing the CD33-CAR T cells were the significant proliferation of CAR T cell, prominent anti-tumor activity, increased level of cytokine production, degranulation, and leukemia burden reduction. The gene discussed is CD33; the disease is neoplasm.